Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 131

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 131
---
 of being realized upon settlement. As of December 31, 2024 and 2023
the Company has not recorded any unrecognized tax benefits.

The
Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
As of December 31, 2024 and 2023, the Company recorded no accrued interest and penalties related to unrecognized tax benefits. The Company
does not expect any significant changes in its tax positions that would warrant recognition of a liability for unrecognized income tax
benefits during the next 12 months.

The
Company files U.S. federal and various state income tax returns and is subject to the examination for tax years back to 2021 and 2020
for federal and state purposes, respectively, and its NOL’s dating back to inception are subject to adjustment by the taxing authorities
if claimed on future tax filings for which the statute remain open to examination. The Company also files Israeli tax returns and is
subject to examination for tax years back to 2020. The Company is not currently under audit by the Internal Revenue Service or other
similar national, state and local authorities.

NOTE
9: SEGMENT INFORMATION

Operating
segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating
decision maker in deciding how to allocate resources in assessing performance. The Company operates as a single reporting segment, focusing
on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company’s chief
operating decision maker (“CODM”) is the chief executive officer.

The
accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses
performance for the segment based on operating expenses as reported in the accompanying consolidated statement of operations. The Company
expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances the development of its
product candidates through pre-clinical and clinical trials. In addition, the measure of segment assets is reported on the accompanying
consolidated balance sheet as total assets.

    F-16

As
such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess
the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus
actual results is used in assessing performance of the segment.

The
following table presents reportable segment loss, including